Marco Sanduzzi-Zamparelli
12PUBLICATIONS
64CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (12)
Sort by Publication Date:
|Feb 23, 2026
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).Marco Sanduzzi-Zamparelli, Ana Matilla, José Luis Lledo
|Aug 12, 2025
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on Immunotherapy.Marta Fortuny, Leonardo G da Fonseca, Manon Allaire
|Jan 24, 2024
Systemic therapies in hepatocellular carcinoma: A revolution?Marta Fortuny, Marco Sanduzzi-Zamparelli, Maria Reig
|Jan 12, 2023
Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis.Ismael El Hajra, Marco Sanduzzi-Zamparelli, Víctor Sapena
|May 24, 2022
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study.Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner
|Jul 06, 2021
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs.Álvaro Díaz-González, Víctor Sapena, Loreto Boix
Pageof 2
Frequent Collaborators
8 joint publications
María Reig
7 joint publications
Jordi Bruix
6 joint publications
Víctor Sapena
6 joint publications
Leonardo G da Fonseca
5 joint publications
Alejandro Forner
4 joint publications
Álvaro Díaz-González
4 joint publications
Neus LLarch
4 joint publications
María Varela
3 joint publications
Ferran Torres
3 joint publications
Gemma Iserte
